New Ovarian Cancer Vaccine Shows Promise
Ovarian cancer is a particularly hard-to-treat disease. It’s often diagnosed late, and even after surgery and chemotherapy, around 85 percent of patients relapse and develop
Ovarian cancer is a particularly hard-to-treat disease. It’s often diagnosed late, and even after surgery and chemotherapy, around 85 percent of patients relapse and develop
Immunotherapy represents one of the major breakthroughs in the treatment of cancer patients. Current therapies focus on harnessing the adaptive immune system, with great success
Scientists from Johns Hopkins, using software from Insilico Medicine, say they have invented a new class of immunotherapeutics to fight cancer. The team published its
Using a process called in situ vaccination, in which the host’s immune system is recruited to attack cancer cells, researchers were able to clear injected
Engineering an immune cell to recognize and kill a cancer cell is the key to chimeric antigen receptor (CAR) T-cell therapy, but modified immune cells
Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need for basic studies of immunoregulation in both adaptive cell lineages
Researchers report promising results in a Phase 1 trial testing a new cell therapy using chimeric antigen receptor (CAR) T-cell technology on patients suffering from
This week, two studies offer a raft of evidence from cancer patients suggesting that the gut microbiome—the community of bacteria, viruses, and other bugs living
Highlights •A prospective trial reveals molecular actions of anti-PD-1 therapy •Anti-PD-1 therapy induces changes in the mutational burden of tumors •Distinct changes in gene expression
In 2010, 5-year-old Emily Whitehead was diagnosed with acute lymphoblastic leukemia (ALL). Though her parents were told that if you had to have a kid
In this issue of Cancer Cell, Saha et al. systematically test and optimize combination therapy strategies in a challenging model of glioblastoma. Durable complete responses
Checkpoint immunotherapy drugs have seen a surge in their adoption as their effectiveness in treating various cancers continues to provide clinical success. Yet, one type
Nivolumab, an immunotherapy drug, has shown unprecedented success at treating patients with certain types of advanced cancer. The U.S. Food and Drug Administration approvals for
T cells eliminate pathogens by recognizing foreign proteins that are expressed on the cell surface (antigens). T cell activation in response to antigen occurs for
Predicting responses to immunotherapy Colon cancers with loss-of-function mutations in the mismatch repair (MMR) pathway have favorable responses to PD-1 blockade immunotherapy. In a phase
Following reports of patient deaths, the FDA has placed clinical holds on three trials assessing Merck & Co.’s approved cancer immunotherapy Keytruda® (pembrolilzumab) in combination
Cancer researchers have shown how the activity of a specific protein enables regulatory T-cells (Tregs) to protect tumors from the immune system’s natural tracking and
Highlights •PD-L1 is primarily regulated by interferon gamma signaling in melanoma cells •PD-L2 is regulated by both interferon beta and gamma signaling •Regulation of PD-1
Exosomes (versatile, cell-derived nanovesicles naturally endowed with exquisite target-homing specificity and the ability to surmount in vivo biological barriers) hold substantial promise for developing exciting
Therapies using T cells that are programmed to express chimeric antigen receptors (CAR T cells) consistently produce positive results in patients with hematologic malignancies. However,
Scientists working to slow the spread of a deadly facial cancer through populations of the Tasmania’s iconic marsupial Sarcophilus harrisii, or the Tasmanian devil, have
Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Kite Pharma today reported positive 6-month data from its pivotal ZUMA-1 trial for its lead chimeric antigen receptor (CAR) T-cell candidate axicabtagene ciloleucel (formerly KTE-C19)
Six months after receiving infusions of their own T cells—genetically engineered ex vivo to carry chimeric antigen receptors (CAR) that bind to proteins on the
Immunotherapies have shown unprecedented efficacy in the treatment of several cancers, including melanoma and lymphoma, and they are now in clinical trials for many others.
Created by ePubSystems. Contact Us for similar site for your university or institute.